Havodil-LS Oral Drops is a combination formulation containing Levosalbutamol (0.25 mg/ml), Ambroxol (7.5 mg/ml), and Guaifenesin (12.5 mg/ml), designed for the management of respiratory conditions characterized by bronchospasm, mucus hypersecretion, and productive cough. Levosalbutamol, a selective β2-adrenergic receptor agonist, acts as a bronchodilator by relaxing bronchial smooth muscles, thereby alleviating bronchospasm and improving airflow in obstructive airway diseases such as asthma and chronic bronchitis. Ambroxol serves as a mucolytic agent, enhancing the clearance of mucus by breaking down its structure, facilitating expectoration, and reducing mucus viscosity. Guaifenesin is an expectorant that promotes the thinning and loosening of mucus in the airways, aiding in the effective clearance of secretions and relieving cough associated with respiratory tract infections. The synergistic action of these active ingredients provides symptomatic relief from bronchial congestion, wheezing, and cough, improving patient comfort and respiratory function. Havodil-LS Oral Drops are indicated for use in pediatric and adult patients with acute and chronic bronchopulmonary conditions where airway obstruction and mucus retention are prominent. Administration should follow prescribed dosage guidelines, and caution is advised in patients with hypersensitivity to any component or with underlying cardiovascular disorders.